<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacol Res</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacol. Res</journal-id><journal-title-group><journal-title>Pharmacological Research</journal-title></journal-title-group><issn pub-type="ppub">1043-6618</issn><issn pub-type="epub">1096-1186</issn><publisher><publisher-name>Elsevier Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7254006</article-id><article-id pub-id-type="publisher-id">S1043-6618(20)31268-8</article-id><article-id pub-id-type="doi">10.1016/j.phrs.2020.104960</article-id><article-id pub-id-type="publisher-id">104960</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system</article-title></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name><surname>Yuan</surname><given-names>Shuofeng</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref><xref rid="fn0005" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="aut0010"><name><surname>Chan</surname><given-names>Jasper F.W.</given-names></name><email>jfwchan@hku.hk</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref><xref rid="aff0015" ref-type="aff">c</xref><xref rid="aff0020" ref-type="aff">d</xref><xref rid="fn0005" ref-type="fn">1</xref><xref rid="cor0005" ref-type="corresp">*</xref></contrib><contrib contrib-type="author" id="aut0015"><name><surname>Chik</surname><given-names>Kenn K.H.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref><xref rid="fn0005" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="aut0020"><name><surname>Chan</surname><given-names>Chris C.Y.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="aut0025"><name><surname>Tsang</surname><given-names>Jessica O.L.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="aut0030"><name><surname>Liang</surname><given-names>Ronghui</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="aut0035"><name><surname>Cao</surname><given-names>Jianli</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="aut0040"><name><surname>Tang</surname><given-names>Kaiming</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="aut0045"><name><surname>Chen</surname><given-names>Lin-Lei</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="aut0050"><name><surname>Wen</surname><given-names>Kun</given-names></name><xref rid="aff0025" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="aut0055"><name><surname>Cai</surname><given-names>Jian-Piao</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="aut0060"><name><surname>Ye</surname><given-names>Zi-Wei</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="aut0065"><name><surname>Lu</surname><given-names>Gang</given-names></name><xref rid="aff0020" ref-type="aff">d</xref><xref rid="aff0030" ref-type="aff">f</xref><xref rid="aff0035" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="aut0070"><name><surname>Chu</surname><given-names>Hin</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="aut0075"><name><surname>Jin</surname><given-names>Dong-Yan</given-names></name><xref rid="aff0040" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="aut0080"><name><surname>Yuen</surname><given-names>Kwok-Yung</given-names></name><email>kyyuen@hku.hk</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref><xref rid="aff0015" ref-type="aff">c</xref><xref rid="aff0020" ref-type="aff">d</xref><xref rid="cor0005" ref-type="corresp">*</xref></contrib><aff id="aff0005"><label>a</label>State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region</aff><aff id="aff0010"><label>b</label>Centre for Virology, Vaccinology and Therapeutics, Health@InnoHK, The University of Hong Kong, Hong Kong Special Administrative Region</aff><aff id="aff0015"><label>c</label>Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China</aff><aff id="aff0020"><label>d</label>Hainan Medical University-The University of Hong Kong Joint Laboratory of Tropical Infectious Diseases, Hainan Medical University, Haikou, China; and The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region</aff><aff id="aff0025"><label>e</label>Division of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China</aff><aff id="aff0030"><label>f</label>Department of Pathogen Biology, Hainan Medical University, Haikou, Hainan, China</aff><aff id="aff0035"><label>g</label>Key Laboratory of Translational Tropical Medicine of Ministry of Education, Hainan Medical University, Haikou, Hainan, China</aff><aff id="aff0040"><label>h</label>School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region</aff></contrib-group><author-notes><corresp id="cor0005"><label>&#x0204e;</label>Corresponding authors at: State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region. <email>jfwchan@hku.hk</email><email>kyyuen@hku.hk</email></corresp><fn id="fn0005"><label>1</label><p id="npar0010">Co-first authors.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>28</day><month>5</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>9</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>28</day><month>5</month><year>2020</year></pub-date><volume>159</volume><fpage>104960</fpage><lpage>104960</lpage><history><date date-type="received"><day>9</day><month>4</month><year>2020</year></date><date date-type="rev-recd"><day>20</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>24</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier Ltd. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier Ltd</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract abstract-type="graphical" id="abs0005"><title>Graphical abstract</title><fig id="fig0035" position="anchor"><graphic xlink:href="ga1_lrg"/></fig></abstract><abstract id="abs0010"><p>Coronavirus Disease 2019 (COVID-19) caused by the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a crude case fatality rate of about 0.5&#x02013;10 % depending on locality. A few clinically approved drugs, such as remdesivir, chloroquine, hydroxychloroquine, nafamostat, camostat, and ivermectin, exhibited anti-SARS-CoV-2 activity <italic>in vitro</italic> and/or in a small number of patients. However, their clinical use may be limited by anti-SARS-CoV-2 50 % maximal effective concentrations (EC<sub>50</sub>) that exceeded their achievable peak serum concentrations (Cmax), side effects, and/or availability. To find more immediately available COVID-19 antivirals, we established a two-tier drug screening system that combines SARS-CoV-2 enzyme-linked immunosorbent assay and cell viability assay, and applied it to screen a library consisting 1528 FDA-approved drugs. Cetilistat (anti-pancreatic lipase), diiodohydroxyquinoline (anti-parasitic), abiraterone acetate (synthetic androstane steroid), and bexarotene (antineoplastic retinoid) exhibited potent <italic>in vitro</italic> anti-SARS-CoV-2 activity (EC<sub>50</sub> 1.13&#x02013;2.01 &#x003bc;M). Bexarotene demonstrated the highest Cmax:EC<sub>50</sub> ratio (1.69) which was higher than those of chloroquine, hydroxychloroquine, and ivermectin. These results demonstrated the efficacy of the two-tier screening system and identified potential COVID-19 treatments which can achieve effective levels if given by inhalation or systemically depending on their pharmacokinetics.</p></abstract><kwd-group id="kwd0005"><title>Chemical compounds studied in this article</title><kwd>Abiraterone acetate (PubChem CID: 9821849)</kwd><kwd>Bexarotene (PubChem CID: 82146)</kwd><kwd>Cetilistat (PubChem CID: 9952916)</kwd><kwd>Diiodohydroxyquinoline (PubChem CID: 3728)</kwd></kwd-group><kwd-group id="kwd0010"><title>Keywords</title><kwd>Antiviral</kwd><kwd>Coronavirus</kwd><kwd>COVID-19</kwd><kwd>Library</kwd><kwd>SARS-CoV-2</kwd><kwd>Treatment</kwd><kwd>Cetilistat</kwd><kwd>Diiodohydroxyquinoline</kwd><kwd>Abiraterone</kwd><kwd>Bexarotene</kwd></kwd-group></article-meta></front><body><sec id="sec0005"><label>1</label><title>Introduction</title><p id="par0005">Coronaviruses are positive sense, single stranded, enveloped RNA viruses that have repeatedly crossed species barriers to cause disease in human and animals [<xref rid="bib0005" ref-type="bibr">1</xref>]. In the past two decades, three novel human-pathogenic coronaviruses have emerged to cause epidemics of severe respiratory infection among human, including severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003, Middle East respiratory syndrome coronavirus (MERS-CoV) since 2012, and most recently SARS-CoV-2 since December 2019 [<xref rid="bib0010" ref-type="bibr">[2]</xref>, <xref rid="bib0015" ref-type="bibr">[3]</xref>, <xref rid="bib0020" ref-type="bibr">[4]</xref>]. Within just 4 months, the number of patients with SARS-CoV-2 infection, or Coronavirus Disease 2019 (COVID-19), has exceeded the total number of cases of SARS and MERS by nearly 100 times, with more than 1.2 million confirmed cases and over 60,000 deaths globally [<xref rid="bib0025" ref-type="bibr">5</xref>]. The clinical severity of COVID-19 ranges from asymptomatic infection to fatal disease. The disease is usually mild in children, but severe infection in immunocompromised and elderly patients may be associated with a crude case fatality rate of about 15 % [<xref rid="bib0030" ref-type="bibr">[6]</xref>, <xref rid="bib0035" ref-type="bibr">[7]</xref>, <xref rid="bib0040" ref-type="bibr">[8]</xref>]. Patient with severe COVID-19 may develop acute respiratory distress syndrome, multiorgan dysfunction syndrome, and other extrapulmonary manifestations such as lymphopenia, diarrhea, confusion, deranged liver and renal function tests, and elevated <sc>d</sc>-dimer, fibrinogen, lactate dehydrogenase, and inflammatory marker levels [<xref rid="bib0045" ref-type="bibr">9</xref>,<xref rid="bib0050" ref-type="bibr">10</xref>]. A major reason for the poor clinical outcome of COVID-19 patients and difficulty in controlling the expansion of the pandemic is the lack of effective vaccine or antiviral for treatment and prophylaxis.</p><p id="par0010">Similar to other emerging viral infections, the <italic>de novo</italic> development of antiviral drugs would inevitably lag behind the rapid progression of the epidemic [<xref rid="bib0055" ref-type="bibr">11</xref>]. Drug repurposing is therefore a feasible strategy to quickly identify clinically approved drugs with known pharmacological properties and safety profiles that can be immediately used in clinical trial settings. A number of existing drugs, such as remedsivir, chloroquine, hydroxychloroquine, nafamostat, camostat, and ivermectin, have been reported to exhibit anti-SARS-CoV-2 activity <italic>in vitro</italic> and/or in a very small number of patients [<xref rid="bib0060" ref-type="bibr">[12]</xref>, <xref rid="bib0065" ref-type="bibr">[13]</xref>, <xref rid="bib0070" ref-type="bibr">[14]</xref>, <xref rid="bib0075" ref-type="bibr">[15]</xref>]. Remdesivir is a nucleotide analogue with broad-spectrum antiviral activities including against SARS-CoV-2 [<xref rid="bib0060" ref-type="bibr">12</xref>]. Chloroquine and hydroxychloroquine are mildly immunosuppressive drugs used in the treatment of autoimmune diseases and malaria that exhibited 50 % maximal effective concentration (EC<sub>50</sub>) at or above the peak serum concentration (Cmax) achievable with standard dosing in human [<xref rid="bib0060" ref-type="bibr">12</xref>,<xref rid="bib0080" ref-type="bibr">16</xref>]. A recent non-randomized small-scale clinical study showed that hydroxychloroquine with or without azithromycin significantly reduced the viral load and duration of virus shedding in 20 COVID-19 patients [<xref rid="bib0065" ref-type="bibr">13</xref>]. Nafamostat and camostat are a serine protease inhibitor used in the treatment of chronic pancreatitis and reflux esophagitis [<xref rid="bib0070" ref-type="bibr">14</xref>]. Ivermectin is a macrocyclic lactone used in the treatment of various parasitic infections [<xref rid="bib0075" ref-type="bibr">15</xref>]. However, data from well-designed randomized controlled trials for these drugs are not yet available. Therefore, there is an urgent need to search for additional drug compounds with anti-SARS-CoV-2 activity among clinically approved drugs. In this study, we first established a robust two-tier drug screening system by combining SARS-CoV-2 enzyme-linked immunosorbent assay with cell viability assay, and then applied it to screen an FDA-approved drug compound library. We successfully identified a number of drug compounds with anti-SARS-CoV-2 activity, including bexarotene which has broad-spectrum anti-coronaviral activity and a higher Cmax to EC<sub>50</sub> ratio than most other reported potential anti-SARS-CoV-2 agents.</p></sec><sec id="sec0010"><label>2</label><title>Materials and methods</title><sec id="sec0015"><label>2.1</label><title>Viruses, cell lines, and drug compounds</title><p id="par0015">SARS-CoV-2 HKU-001a (GenBank accession number: MT230904&#x0200b;) was isolated from the nasopharyngeal aspirate specimen of a laboratory-confirmed COVID-19 patient in Hong Kong [<xref rid="bib0085" ref-type="bibr">17</xref>]. MERS-CoV EMC/2012 strain (GenBank accession number: NC_019843.3) was kindly provided by Ron Rouchier (Erasmus Medical Center, Rotterdam, the Netherlands) [<xref rid="bib0090" ref-type="bibr">18</xref>]. The viruses were propagated in VeroE6 cells and kept at &#x02212;80 &#x000b0;C in aliquots until use. Plaque forming unit (PFU) and TCID<sub>50</sub> assays were performed to titrate the cultured SARS-CoV-2. VeroE6 (ATCC&#x000ae; CRL-1586&#x02122;) and Caco2 cells (ATCC&#x000ae; HTB-37&#x02122;) were purchased from ATCC and maintained in Dulbecco&#x02019;s modified eagle medium (DMEM, Gibco, CA, USA) culture medium supplemented with 10 % heat-inactivated fetal bovine serum (FBS, Gibco), 50 U/mL penicillin, and 50 &#x003bc;g/ml streptomycin as previously described [<xref rid="bib0085" ref-type="bibr">17</xref>]. All experiments involving live SARS-CoV-2 and MERS-CoV followed the approved standard operating procedures of the Biosafety Level 3 facility at the Department of Microbiology, The University of Hong Kong, as previously described [<xref rid="bib0095" ref-type="bibr">19</xref>,<xref rid="bib0100" ref-type="bibr">20</xref>]. The FDA-approved drug library (Cat# HY-L022) and all the tested drug compounds were purchased from MedChem Express (Monmouth Junction, NJ, USA).</p></sec><sec id="sec0020"><label>2.2</label><title>Cell viability assay and CPE inhibition assay</title><p id="par0020">The CellTiterGlo&#x000ae; luminescent assay (Promega Corporation, Madison, WI, USA) was performed to detect the cytotoxicity of the selected drug compounds as previously described [<xref rid="bib0105" ref-type="bibr">21</xref>]. Briefly, VeroE6 cells (4 &#x000d7; 10<sup>4</sup> cells/well) were incubated with different concentrations of the individual compound for 48 h, followed by the addition of substrate and measurement of luminance 10 min later. The CC<sub>50</sub> of the drug compounds were calculated by Sigma plot (SPSS) in an Excel add-in ED50V10. The CPE inhibition assay was performed as previously described with slight modifications to evaluate the individual drug compounds&#x02019; cell protection effects against SARS-CoV-2 infection [<xref rid="bib0105" ref-type="bibr">21</xref>]. Briefly, VeroE6 cells seeded in 96-well plates were infected with SARS-CoV-2 for 1 h with 0.01 multiplicity of infection (MOI), followed by washing with phosphate-buffered saline (PBS) and replacement of fresh DMEM medium containing serially diluted drug compounds and 0.1 % DMSO as negative control. The cell viability of each well was determined at 3 days post-infection (dpi) by the CellTiterGlo&#x000ae; luminescent assay.</p></sec><sec id="sec0025"><label>2.3</label><title>ELISA</title><p id="par0025">ELISA was performed to determine the amount of viral N protein expression in the culture supernatant of SARS-CoV-2-infected cells using a similar approach as previously described [<xref rid="bib0110" ref-type="bibr">22</xref>]. Briefly, 500 ng/well of mouse-anti-SARS-CoV-N monoclonal antibody (clone 14E7A11A8) was coated in 96-well ELISA plates for overnight incubation at 4 &#x000b0;C, followed by blocking with 2.5 % FBS plus 2.5 % FBS in PBS with Tween 20 (Sigma-Aldrich, St. Louis, MO, USA) for 2 h at 37 &#x000b0;C. After washing, the infectious culture supernatants were transferred to the ELISA plates accordingly (50 &#x003bc;L, incubated at room temperature for 2 h), followed by intensive wash and addition of another 50 &#x003bc;L/well rabbit anti-SARS-CoV-N polyclonal antibody (1:4000), the secondary goat-anti-rabbit horseradish peroxidase (HRP) antibody (1:1500, Invitrogen, Carlsbad, CA, USA), the 3,3&#x02032;,5,5&#x02032;-tetramethylbenzidine (TMB) solution (Invitrogen), and the stop solution (0.1 M HCl). Subsequently, the optical density of each well was read at 450 nm (OD450) using VICTOR 3 multi-label plate reader (PerkinElmer, Inc., Waltham, MA, USA). The rabbit anti-SARS-CoV-N monoclonal antibody showed good cross-reactivity against SARS-CoV-2-N [<xref rid="bib0085" ref-type="bibr">17</xref>,<xref rid="bib0115" ref-type="bibr">23</xref>].</p></sec><sec id="sec0030"><label>2.4</label><title>FDA drug compound library screening</title><p id="par0030">To identify anti-SARS-CoV-2 inhibitors, confluent VeroE6 cells in 96-well culture plates (4 &#x000d7; 10<sup>4</sup> cells/well) in triplicates were infected with SARS-CoV-2 at 0.004 MOI. One hour after virus adsorption, the inoculum was removed and then drug-containing medium (10&#x003bc;M) was added. Next, after 72 h, 20 &#x003bc;L of cell culture supernatant was diluted into 80 &#x003bc;L of PBS before adding to the antibody-coated ELISA plate for SARS-CoV-2-N detection, while another 20 &#x003bc;L/well of CellTiterGlo&#x000ae; substrate was added to the original cell culture plates for cell viability evaluation by CPE inhibition assay.</p></sec><sec id="sec0035"><label>2.5</label><title>Viral load reduction assay</title><p id="par0035">Viral load reduction assay was performed on VeroE6 and Caco2 cells, as described previously with modifications [<xref rid="bib0120" ref-type="bibr">24</xref>,<xref rid="bib0125" ref-type="bibr">25</xref>]. Supernatant samples from the infected cells were harvested at different time-points for qRT-PCR analysis of virus replication. Briefly, 100 &#x003bc;l of viral supernatant was lyzed with 400 &#x003bc;l of AVL buffer and then extracted for total RNA with the QIAamp viral RNA mini kit (Qiagen, Hilden, Germany). Real-time one-step qRT-PCR was used for quantitation of SARS-CoV-2 and SARS-CoV viral load using the QuantiNova Probe RT-PCR kit (Qiagen) with a LightCycler 480 Real-Time PCR System (Roche) as previously described [<xref rid="bib0130" ref-type="bibr">26</xref>]. Each 20 &#x003bc;l reaction mixture contained 10 &#x003bc;l of 2&#x000d7;QuantiNova Probe RT-PCR Master Mix, 1.2 &#x003bc;l of RNase-free water, 0.2 &#x003bc;l of QuantiNova Probe RT-Mix, 1.6 &#x003bc;l each of 10 &#x003bc;M forward and reverse primer, 0.4 &#x003bc;l of 10 &#x003bc;M probe, and 5 &#x003bc;l of extracted RNA as the template. Reactions were incubated at 45 &#x000b0;C for 10 min for reverse transcription, 95 &#x000b0;C for 5 min for denaturation, followed by 45 cycles of 95 &#x000b0;C for 5 s and 55 &#x000b0;C for 30 s. Signal detection and measurement were taken in each cycle after the annealing step. The cycling profile ended with a cooling step at 40 &#x000b0;C for 30 s. The primers and probe sequences were against the RNA-dependent RNA polymerase/Helicase (RdRP/Hel) gene region of SARS-CoV-2: Forward primer: 5&#x02032; CGCATACAGTCTTRCAGGCT-3&#x02032;; Reverse primer: 5&#x02032;-GTGTGATGTTGAWATGACATGGTC-3&#x02032;; specific probe: 5&#x02032;-FAM TTAAGATGTGGTGCTTGCATACGTAGAC-IABkFQ-3&#x02032; [<xref rid="bib0130" ref-type="bibr">26</xref>].</p></sec><sec id="sec0040"><label>2.6</label><title>Plaque reduction assay</title><p id="par0040">Plaque reduction assay was performed to plot the 50 % antiviral effective dose (EC<sub>50</sub>) as we previously described with slight modifications [<xref rid="bib0120" ref-type="bibr">24</xref>,<xref rid="bib0135" ref-type="bibr">27</xref>]. Briefly, VeroE6 cells were seeded at 4 &#x000d7; 10<sup>5</sup> cells/well in 12-well tissue culture plates on the day before carrying out the assay. After 24 h of incubation, 50 plaque-forming units (PFU) of SARS-CoV-2 were added to the cell monolayer with or without the addition of drug compounds and the plates were further incubated for 1 h at 37 &#x000b0;C in 5% CO<sub>2</sub> before removal of unbound viral particles by aspiration of the media and washing once with DMEM. Monolayers were then overlaid with media containing 1% low melting agarose (Cambrex Corporation, New Jersey, USA) in DMEM and appropriate concentrations of individual compound, inverted and incubated as above for another 72 h. The wells were then fixed with 10 % formaldehyde (BDH, Merck, Darmstadt, Germany) overnight. After removal of the agarose plugs, the monolayers were stained with 0.7 % crystal violet (BDH, Merck) and the plaques counted. The percentage of plaque inhibition relative to the control (<italic>i.e.</italic> without the addition of compound) wells were determined for each drug compound concentration. The EC<sub>50</sub> was calculated using Sigma plot (SPSS) in an Excel add-in ED50V10. The plaque reduction assay experiments were performed in triplicate and repeated twice for confirmation.</p></sec><sec id="sec0045"><label>2.7</label><title>Time-of-drug-addition assay</title><p id="par0045">Time-of-drug-addition assay was performed for the selected compound as previously described with slight modifications [<xref rid="bib0125" ref-type="bibr">25</xref>]. Briefly, VeroE6 cells were seeded in 24-well plates (2 &#x000d7; 10<sup>5</sup> cells/well). The cells were inoculated with SARS-CoV-2 (MOI = 0.500) and then incubated for 1 h for virus internalization. Drugs were added at different time points of the virus replication cycle, including: pre-treatment (From -2 h post infection (hpi) to -1 hpi), co-infection with virus (-1 to 0 hpi) or post-infection (0 to +1 hpi). Dimethyl sulfoxide (0.5 %) was included as a negative control. Other details were depicted as schematic representations in <xref rid="fig0030" ref-type="fig">Fig. 6</xref>.</p></sec><sec id="sec0050"><label>2.8</label><title>Immunofluorescence staining</title><p id="par0050">Antigen expression in SARS-CoV-2-infected cells was detected with an in-house rabbit antiserum against SARS-CoV-N protein, which cross-reacted with the SARS-CoV-2-N protein due to their high amino acid homologies [<xref rid="bib0085" ref-type="bibr">17</xref>,<xref rid="bib0115" ref-type="bibr">23</xref>]. Cell nuclei were labelled with the DAPI nucleic acid stain from Thermo Fisher Scientific (Waltham, MA, USA). The Alexa Fluor secondary antibody was obtained from Thermo Fisher Scientific. Mounting was performed with the Diamond Prolong Antifade mountant from Thermo Fisher Scientific.</p></sec></sec><sec id="sec0055"><label>3</label><title>Results</title><sec id="sec0060"><label>3.1</label><title>Characterization of SARS-CoV-2 replication kinetics</title><p id="par0055">To develop a drug screening system for SARS-CoV-2, we first characterized the viral replication kinetics of SARS-CoV-2 in VeroE6 cells and compared the signal dynamic range utilizing three approaches. These approaches included luminescent cell viability assay with CellTiterGlo&#x000ae; for evaluation of virus induced-cytopathic effects (CPE), viral load quantitation assay with quantitative RT-PCR (qRT-PCR) targeting the viral RNA-dependent RNA polymerase (RdRp)/ helicase (Hel) genes, and viral nucleocapsid (N) protein expression with enzyme-linked immunosorbent assay (ELISA). VeroE6 cells were used because they robustly support SARS-CoV-2 replication [<xref rid="bib0085" ref-type="bibr">17</xref>]. Time-dependent observation of CPE development was recorded using different multiplicities of infection (MOI) (1.000, 0.250, 0.063, 0.016, and 0.004). SARS-CoV-2 infection (MOI = 1.000) caused significant CPE in VeroE6 cells as early as 48 h post-infection (hpi) (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>
A). At 72 hpi, prominent CPE were detected in the virus-infected VeroE6 cells even with the lowest MOI of 0.004, while the morphology of the non-infected VeroE6 cells remained intact. This observation was in line with the cell viability determined by using the CellTiter-Glo&#x000ae; substrate, which is a reagent that generates a luminescent signal directly proportional to the amount of adenosine triphosphate (ATP) present and is proportional to the number of metabolically active cells. As shown in <xref rid="fig0005" ref-type="fig">Fig. 1</xref>B, there was approximately 75 % reduction in cell viability at 48 hpi with MOI of 1.000, 0.250, or 0.063 and at 72 hpi with MOI of 0.016 or 0.004. In the qRT-PCR assay, viral RNA load in the culture supernatant markedly increased by &#x02265;2 logs gene copies per reaction within 24 hpi (&#x0223c;2 logs for 0.004 MOI, &#x0223c;3 logs for 0.016 MOI, and &#x0223c;3.5 logs for 0.063, 0.250, and 1.000 MOI) (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>C). Regardless of the MOI, the viral RNA load plateaued at 48 hpi. The viral N protein expression followed a delayed but similar pattern as that of the viral RNA load, with the peak viral antigen expression being observed at 72 hpi (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>D).<fig id="fig0005"><label>Fig. 1</label><caption><p><bold>Development of a two-tier system for anti-SARS-CoV-2 drug compound screening.</bold> VeroE6 cells seeded in a 96-well plate were infected with SARS-CoV-2 of various multiplicities of infection (MOIs)) as indicated, followed by phosphate buffered saline (PBS) wash and replacement of fresh Dulbecco&#x02019;s modified eagle medium (DMEM). Various time points of data collection were performed for (A) Cytopathic effects (CPE) observed by a bright-field at 20&#x000d7; magnification. (B) Cell viability of each treatment group normalized with that of the mock-infected cells. (C) Cell culture supernatant was collected at the indicated time points with viral copy number determined by quantitative RT-PCR (qRT-PCR). (D) The supernatant was concomitantly applied for ELISA to measure the SARS-CoV-2-nucleoprotein (NP) protein amount. The experiments were carried out in triplicate. The results are shown as mean &#x000b1; standard deviation.</p></caption><alt-text id="at0005">Fig. 1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p></sec><sec id="sec0065"><label>3.2</label><title>Establishment of a two-tier drug screening system for rapid identification of antivirals against SARS-CoV-2 from an FDA-approved drug compound library</title><p id="par0060">The signal window is determined by the upper and lower boundaries of the assay readout and is considered a major parameter for the overall assay quality measurement. The qRT-PCR assay exhibited the highest signal window (&#x0223c;4 log difference between SARS-CoV-2-infected and non-infected samples) but was laborious, and was thus inefficient as a high-throughput drug compound screening assay. On the other hand, the ELISA (&#x0223c;6 folds) and cell viability assay (&#x0223c;4 folds) also exhibited reasonably high signal differences between infected cells and baseline at 72 hpi and provided a wide signal window. Therefore, we exploited the combination of ELISA and cell viability assay as a two-tier drug screening system for finding potential SARS-CoV-2 antivirals. This combinational screening system is rapid, non-labor-intensive, and can easily exclude false-positive results due to cytotoxicity. Using this newly established system, we screened an FDA-approved drug library containing 1528 drug compounds under the optimized conditions of 0.004 MOI at 72 hpi with each drug concentration fixed at 10&#x003bc;M. At 72 hpi, 20 &#x003bc;L/well of cell culture supernatant was harvested for SARS-CoV-2-N detection before addition of another 40 &#x003bc;L/well CellTiter-Glo&#x000ae; substrate for determination of cell viability (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>
). Among the 1528 drug compounds, we identified 34 primary hit drug compounds with &#x02265;4-fold reduction of detection signal in ELISA. In the secondary screen by cell viability assay, 19 of these 34 drug compounds showed &#x0003c;10 % CPE at 72 hpi (<xref rid="tbl0005" ref-type="table">Table 1</xref>
). Notably, hydroxychloroquine, nafamostat, and ivermectin which were previously shown to exhibit anti-SARS-CoV-2 activity were also identified in our primary screen with ELISA, but they showed &#x0003e;10 % CPE at 72 hpi and were therefore excluded from the 19 drug compound list. Camostat was not detected in the primary screen but this might be related to its EC<sub>50</sub> being higher than 10&#x003bc;M which was used in our primary screen. Remdesivir was not included in the library and was therefore not identified.<fig id="fig0010"><label>Fig. 2</label><caption><p><bold>Schematic representation of the study design.</bold> Using the newly established two-tier drug compound screening system, an FDA-approved drug compound library consisting 1528 drug compounds was screened for potential anti-SARS-CoV-2 agents. Primary screening by ELISA identified 34 drug compounds with 4-fold reduction in the detection signal. Secondary screening by cell viability assay further selected 19 of the 34 drug compounds that exhibited &#x02265;90 % cell viability. Four drug compounds were then prioritized for cytotoxicity and antiviral activity evaluation by plaque reduction and viral load reduction assays.</p></caption><alt-text id="at0010">Fig. 2</alt-text><graphic xlink:href="gr2_lrg"/></fig><table-wrap position="float" id="tbl0005"><label>Table 1</label><caption><p>Primary hit drug compounds identified from an FDA-approved drug library with a two-tier drug screening platform for SARS-CoV-2.</p></caption><alt-text id="at0035">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Compound</th><th align="left">Drug class</th><th align="left">Main clinical use(s)</th></tr></thead><tbody><tr><td align="left">Abiraterone (acetate)</td><td align="left">Synthetic androstane steroid</td><td align="left">Prostate cancer</td></tr><tr><td align="left">Asenapine (hydrochloride)</td><td align="left">Atypical antipsychotic</td><td align="left">Schizophrenia</td></tr><tr><td align="left">Azacytidine</td><td align="left">Nucleoside analogue</td><td align="left">Myelodysplastic syndrome and acute myeloid leukemia</td></tr><tr><td align="left">Bexarotene</td><td align="left">Retinoid (retinoid X receptor activator)</td><td align="left">Cutaneous T cell lymphoma</td></tr><tr><td align="left">Candesartan (Cilexetil)</td><td align="left">Angiotensin receptor blocker</td><td align="left">Hypertension and congestive heart failure</td></tr><tr><td align="left">Cetilistat</td><td align="left">Pancreatic lipase inhibitor</td><td align="left">Obesity</td></tr><tr><td align="left">Chloroquine (diphosphate)</td><td align="left">4-Aminoquinoline</td><td align="left">Malaria and amoebic liver abscess</td></tr><tr><td align="left">Ciclesonide</td><td align="left">Glucocorticoid</td><td align="left">Asthma and allergic rhinitis</td></tr><tr><td align="left">Diethylstilbestrol</td><td align="left">Nonsteroidal estrogen</td><td align="left">Prostate cancer</td></tr><tr><td align="left">Diiodohydroxyquinoline</td><td align="left">Quinoline derivative</td><td align="left">Amoebiasis</td></tr><tr><td align="left">Fluoxetine (hydrochloride)</td><td align="left">Selective serotonin reuptake inhibitor</td><td align="left">Depression</td></tr><tr><td align="left">Micafungin (sodium)</td><td align="left">Echinocandin</td><td align="left">Fungal infection</td></tr><tr><td align="left">Permethrin</td><td align="left">Insecticide</td><td align="left">Scabies and lice</td></tr><tr><td align="left">Pimavanserin</td><td align="left">Atypical antipsychotic</td><td align="left">Parkinson&#x02019;s disease psychosis</td></tr><tr><td align="left">Raloxifene (hydrochloride)</td><td align="left">Selective estrogen receptor modulator</td><td align="left">Osteoporosis</td></tr><tr><td align="left">Sofalcone</td><td align="left">Synthetic sophoradin analogue</td><td align="left">Gastrointestinal tract mucosal protection</td></tr><tr><td align="left">Tamoxifen (Citrate)</td><td align="left">Selective estrogen receptor modulator</td><td align="left">Breast cancer, infertility, and gynecomastia</td></tr><tr><td align="left">Tilorone (dihydrochloride)</td><td align="left">Interferon inducer</td><td align="left">Antiviral</td></tr><tr><td align="left">Tocofersolan</td><td align="left">Synthetic vitamin E</td><td align="left">Vitamin E deficiency</td></tr></tbody></table></table-wrap></p></sec><sec id="sec0070"><label>3.3</label><title><italic>In vitro</italic> antiviral evaluation of the selected drug compounds</title><p id="par0065">Next, these 19 primary hit drug compounds were subjected to viral load reduction assay for prioritization based on their dose-dependent anti-SARS-CoV-2 effects. Four drug compounds, namely, cetilistat, diiodohydroxyquinoline, abiraterone acetate, and bexarotene were identified as the most potent anti-SARS-CoV-2 drug compounds using the cut-off of 90 % effective concentrations (EC<sub>90</sub>) &#x0003c;10 &#x003bc;M after treating VeroE6 cells with 0.01 MOI of SARS-CoV-2 for 48 h. Using plaque reduction assay, the EC<sub>50</sub> of the drug compounds were determined to be 1.13 &#x003bc;M (cetilistat), 1.38&#x003bc;M (diiodohydroxyquinoline), 1.94 &#x003bc;M (abiraterone acetate), and 2.01 &#x003bc;M (bexarotene) (<xref rid="fig0015" ref-type="fig">Fig. 3</xref>
A&#x02013;D). At 48 hpi, the 50 % cytotoxic concentrations (CC<sub>50</sub>) of cetilistat, diiodohydroxyquinoline, abiraterone acetate, and bexarotene were &#x0003e;100 &#x003bc;M, &#x0003e;100 &#x003bc;M, 92.35 &#x003bc;M, and 38.21 &#x003bc;M, respectively (<xref rid="tbl0010" ref-type="table">Table 2</xref>
). The selectivity index of these four drug compounds were &#x0003e;88.50 (cetilistat), &#x0003e;72.46 (diiodohydroxyquinoline), 47.60 (abiraterone acetate), and 19.01 (bexarotene), respectively.<fig id="fig0015"><label>Fig. 3</label><caption><p><bold>Identification of four FDA-approved drug compounds with potent anti-SARS-CoV-2 activity.</bold> Chemical structures of the selected compounds and photos of plaque reduction assay are shown: (A) cetilistat, (B) diiodohydroxyquinoline, (C) abiraterone acetate, and (D) bexarotene.</p></caption><alt-text id="at0015">Fig. 3</alt-text><graphic xlink:href="gr3_lrg"/></fig><table-wrap position="float" id="tbl0010"><label>Table 2</label><caption><p>Antiviral activity and cytotoxicity of the four most potent drug compounds.</p></caption><alt-text id="at0040">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Compound</th><th align="left">CC<sub>50</sub> (&#x003bc;M)<break/>(CellTiterGlo&#x000ae;)<xref rid="tblfn0005" ref-type="table-fn">a</xref></th><th align="left">EC<sub>90</sub> (&#x003bc;M)<break/>(viral load reduction assay)</th><th align="left">EC<sub>50</sub> (&#x003bc;M)<break/>(plaque reduction assay)</th><th align="left">Select index<break/>(CC<sub>50</sub>/EC<sub>50</sub>)</th></tr></thead><tbody><tr><td align="left">Cetilistat</td><td align="left">&#x0003e;100.00</td><td align="left">2.90</td><td align="left">1.13</td><td align="left">&#x0003e;88.50</td></tr><tr><td align="left">Diiodohydroxyquinoline</td><td align="left">&#x0003e;100.00</td><td align="left">4.50</td><td align="left">1.38</td><td align="left">&#x0003e;72.46</td></tr><tr><td align="left">Abiraterone (acetate)</td><td align="left">92.35</td><td align="left">8.40</td><td align="left">1.94</td><td align="left">47.60</td></tr><tr><td align="left">Bexarotene</td><td align="left">38.21</td><td align="left">9.40</td><td align="left">2.01</td><td align="left">19.01</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: CC<sub>50</sub>, 50 % cytotoxic concentration; EC<sub>50</sub>, 50 % maximal effective concentration; EC<sub>90</sub>, 90 % maximal effective concentration.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0005"><label>a</label><p id="npar0005">&#x0003e;100 indicates the highest drug concentration tested in the cytotoxicity assay was 100&#x003bc;M.</p></fn></table-wrap-foot></table-wrap></p><p id="par0070">To more clearly demonstrate the anti-SARS-CoV-2 activities of these four identified drug compounds, we included remdesivir as a comparator drug. Similar to remdesivir, treatment with any one of the four drug compounds below the non-toxic drug concentration of 10&#x003bc;M, markedly suppressed SARS-CoV-2-N protein expression (<xref rid="fig0020" ref-type="fig">Fig. 4</xref>
). As shown in <xref rid="fig0025" ref-type="fig">Fig. 5</xref>
A, all four drug compounds exhibited dose-dependent viral load reduction with magnitudes of 1 log to 3 logs. At 10&#x003bc;M of drug concentration, treatment with cetilistat exhibited about 3 logs reduction at 48 hpi, as comparable level achieved by remdesivir which demonstrated an EC<sub>50</sub> of 1.04&#x003bc;M in our study. Similar levels of dose-dependent viral load reduction were observed in SARS-CoV-2-infected Caco2 (human colorectal adenocarcinoma) cell culture supernatants and cell lysates (<xref rid="fig0025" ref-type="fig">Fig. 5</xref>B). In addition to viral load reduction, treatment with any one of these four drug compounds provided cell protection effects. In the CPE inhibition assay, treatment with 10&#x003bc;M of cetilistat completely inhibited CPE development in VeroE6 cells at 72 hpi, while diiodohydroxyquinoline, abiraterone acetate, and bexarotene achieved up to &#x0223c;70 % CPE inhibition (<xref rid="fig0025" ref-type="fig">Fig. 5</xref>C). Overall, these results demonstrated that cetilistat, diiodohydroxyquinoline, abiraterone acetate, and bexarotene inhibited the viral load, viral antigen expression, and infectious viral particle production of SARS-CoV-2, and protected SARS-CoV-2-induced cell damages at comparable levels of remdesivir.<fig id="fig0020"><label>Fig. 4</label><caption><p><bold>Immunofluorescence staining showing the anti-SARS-CoV-2 effects of the four selected drug compounds.</bold> Fixation and staining were performed on SARS-CoV-2-infected (MOI = 0.100) VeroE6 cells after treatment with cetilistat, diiodohydroxyquinoline, abiraterone acetate, or bexarotene (10&#x003bc;M each) and incubated at 37 &#x000b0;C with 5% CO<sub>2</sub> for 24 h. The SARS-CoV-2-N antigens and cell nuclei (DAPI) were stained in green and blue, respectively. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).</p></caption><alt-text id="at0020">Fig. 4</alt-text><graphic xlink:href="gr4_lrg"/></fig><fig id="fig0025"><label>Fig. 5</label><caption><p><bold>Characterization of the anti-SARS-CoV-2 activity of each of the four selected drug compounds <italic>in vitro</italic>.</bold> (A) VeroE6 and (B) Caco2 cells were infected with SARS-CoV-2 and treated with different concentrations of the selected drug compounds as indicated. The viral load under each condition was collected at 48 hpi for viral load reduction assay by qRT-PCR. Intracellular viral loads were normalized by human &#x003b2;-actin. (C) VeroE6 cells were infected with SARS-CoV-2 and treated with different concentrations of the selected drug compounds as indicated and evaluated by the CPE inhibition assay at 72 hpi. Remdesivir was used as a positive control in all of these experiments. One-way ANOVA was used to compare the treatment groups with the 0&#x003bc;M (negative control) group. *P indicates &#x0003c; 0.05 and ** indicates P &#x0003c; 0.01 (Student&#x02019;s t-test). All the experiments were performed in triplicate and replicated twice. The results are shown as mean &#x000b1; standard deviations.</p></caption><alt-text id="at0025">Fig. 5</alt-text><graphic xlink:href="gr5_lrg"/></fig></p></sec><sec id="sec0075"><label>3.4</label><title>Modes of action of cetilistat, diiodohydroxyquinoline, abiraterone acetate, and bexarotene against SARS-CoV-2</title><p id="par0075">To investigate which steps of the SARS-CoV-2 replication cycle were interrupted by the selected drug compounds, we performed a time-of-drug-addition assay by treating virus-infected VeroE6 cells to each drug compound at different time points, followed by viral titer measurements at 9 hpi, when the first round of progeny virions were detectable in the cell culture supernatant. VeroE6 cells were infected by 0.500 MOI of SARS-CoV-2, before and after which four different treatments were carried out (<xref rid="fig0030" ref-type="fig">Fig. 6</xref>
A). Addition of cetilistat, diiodohydroxyquinoline, or abiraterone acetate at 0 hpi and 3 hpi, but not pre-treatment with host cells or during virus adsorption (co-infection) significantly reduced viral replication, suggesting that these three drug compounds disrupted the post-entry events of the SARS-CoV-2 replication cycle (<xref rid="fig0030" ref-type="fig">Fig. 6</xref>B). In contrast, bexarotene was only effective when co-infected with cells, suggesting that it interfered with virus entry either by blocking the host ACE2 receptor or the viral components required for cell attachment and entry. To further delineate the step of SARS-CoV-2 entry that is affected by bexarotene, VeroE6 cells were placed at 4 &#x000b0;C for 2 h which only permitted virus attachment to the cell surface and then at 37 &#x000b0;C for 1 h which enabled virus internalization (<xref rid="fig0030" ref-type="fig">Fig. 6</xref>C). As shown in <xref rid="fig0030" ref-type="fig">Fig. 6</xref>D, bexarotene did not block virus-host receptor binding, but significantly reduced viral load during virus internationalization. These results suggested that bexarotene interfered with SARS-CoV-2 internalization without blocking its binding to the host cell surface. Interestingly, bexarotene also demonstrated antiviral activity against the highly virulent MERS-CoV (EC<sub>50</sub> of 2.12 &#x003bc;M), suggesting that it has the potential of being a &#x0201c;pan-coronavirus&#x0201d; antiviral (<xref rid="fig0030" ref-type="fig">Fig. 6</xref>E).<fig id="fig0030"><label>Fig. 6</label><caption><p><bold>Anti-SARS-CoV-2 modes of action of the four selected drug compounds.</bold> (A) Time-of-drug-addition assay was performed to determine the steps of the viral replication cycle targeted by each of the four identified drug compounds. The assay was conducted at 37 &#x000b0;C. (B) Viral load in the treated VeroE6 cell culture supernatants normalized by DMSO as control. (C) Virus entry assay with or without bexarotene addition. Viral attachment was performed at 4&#x02103; and then shifted to 37&#x02103; to enable virus internalization. (D) Intracellular viral load in the treated VeroE6 cells normalized by DMSO as control. (E) Viral load reduction assay showing the dose-dependent anti-MERS-CoV activity of bexarotene (10&#x003bc;M). VeroE6 cells were infected with MERS-CoV (MOI = 0.01) and treated with bexarotene, and the culture supernatant was then collected at 48 h post-inoculation for viral load quantitation by qRT-PCR. *P indicates &#x0003c; 0.05 and ** indicates P &#x0003c; 0.01 (Student&#x02019;s t-test). All the experiments were performed in triplicate and replicated twice. The results are shown as mean &#x000b1; standard deviations.</p></caption><alt-text id="at0030">Fig. 6</alt-text><graphic xlink:href="gr6_lrg"/></fig></p></sec></sec><sec id="sec0080"><label>4</label><title>Discussion</title><p id="par0080">The newly established two-tier screening system in this study was robust and able to identify other drug compounds that were shown to exhibit anti-SARS-CoV-2 activity, including chloroquine, hydroxychloroquine, ivermectin, and nafamostat. This allowed us to rapidly and systematically screen a drug library consisting 1528 FDA-approved drug compounds and identify four drug compounds that showed anit-SARS-CoV-2 activities at low micromolar concentrations (EC<sub>50</sub> = 1.13&#x02013;2.01). Cetilistat is a pancreatic lipase inhibitor that blocks fat digestion and absorption used in the treatment of obesity [<xref rid="bib0140" ref-type="bibr">28</xref>]. Diiodohydroxylquinoline, also known as uidoquinol, is a quinolone derivative that is used as a luminal amebicide for the treatment of amoebiasis [<xref rid="bib0145" ref-type="bibr">29</xref>]. Cetilistat is rapidly hydrolyzed into its metabolites in the presence of bile and diiodohydroxylquinoline is poorly absorbed into circulatory system [<xref rid="bib0140" ref-type="bibr">28</xref>,<xref rid="bib0150" ref-type="bibr">30</xref>]. Importantly, about 15&#x02013;20 % of COVID-19 patients develop gastrointestinal symptoms with some also having detectable viral RNA and even infectious virus particles [<xref rid="bib0155" ref-type="bibr">31</xref>]. In a SARS-CoV-2-infected hamster model, it was found that the animals&#x02019; intestines exhibited severe inflammation with detectable viral RNA and abundant viral nucleocapsid protein expression [<xref rid="bib0115" ref-type="bibr">23</xref>]. These findings showed that like in SARS, feces might also be a potential source of infection in COVID-19 [<xref rid="bib0010" ref-type="bibr">2</xref>,<xref rid="bib0160" ref-type="bibr">32</xref>]. Thus, besides being administered by inhalation, oral cetilisat and diiodohydroxylquinoline might have a role as topical luminal antivirals to reduce viral shedding in the gastrointestinal tract.</p><p id="par0085">Both abiraterone acetate and bexarotene are non-chemotherapeutic antineoplastic drugs with limited immunosuppressive effects. Abiraterone acetate is used in combination with corticosteroid to treat refractory prostate cancer through androgen deprivation by inhibition of the androgen synthesizing enzyme CYP17A1 [<xref rid="bib0165" ref-type="bibr">33</xref>,<xref rid="bib0170" ref-type="bibr">34</xref>]. Bexarotene is a third-generation retinoid used in the treatment of cutaneous T cell lymphoma, non-small cell lung cancer, and breast cancer [<xref rid="bib0175" ref-type="bibr">[35]</xref>, <xref rid="bib0180" ref-type="bibr">[36]</xref>, <xref rid="bib0185" ref-type="bibr">[37]</xref>, <xref rid="bib0190" ref-type="bibr">[38]</xref>]. We showed that abiraterone acetate and bexarotene potently inhibited SARS-CoV-2 replication <italic>in vitro</italic> with EC<sub>50</sub> of 1.94 &#x003bc;M and 2.01 &#x003bc;M, respectively. Of particular interest is bexarotene which has a peak serum concentration (Cmax) of 3.39 &#x003bc;M after an oral dose of 300 mg/m<sup>2</sup> [<xref rid="bib0195" ref-type="bibr">39</xref>]. The Cmax to EC<sub>50</sub> ratio of bexarotene for SARS-CoV-2 (1.69) is higher than those achieved with standard dosing of chloroquine, hydroxychloroquine, and ivermectin (0.02&#x02013;1.04). Moreover, the time required to achieve Cmax (Tmax) with standard oral dosing of bexarotene is short (2.5 h), which is important especially in COVID-19 patients who are acutely ill with rapid clinical deterioration [<xref rid="bib0195" ref-type="bibr">39</xref>]. We have previously shown that AM580 and tamibarotene, which belong to the same drug class as bexarotene, exhibited broad-spectrum antiviral activities against coronaviruses (MERS-CoV and SARS-CoV), influenza viruses, enterovirus A71, Zika virus, and adenovirus [<xref rid="bib0105" ref-type="bibr">21</xref>]. We therefore additionally tested the antiviral activity of bexarotene against the highly virulent MERS-CoV, and showed that it indeed also inhibited MERS-CoV with an EC<sub>50</sub> of 2.12 &#x003bc;M. The potential of bexarotene and its related analogue compounds as &#x0201c;pan-coronavirus&#x0201d; agents should be further evaluated in suitable animal models for COVID-19 and other human-pathogenic coronaviruses.</p><p id="par0090">In conclusion, the robust two-tier drug compound screening system established in this study represented a novel platform for conducting drug discovery programmes for COVID-19. The topical and/or systemic effects of cetilistat, diiodohydroxylquinoline, abiraterone acetate, and bexarotene should be further evaluated in suitable <italic>ex vivo</italic> human organ culture or organoids, animal models, and/or clinical trials.</p></sec><sec id="sec0085"><title>Author contributions</title><p id="par0095">SY, JFWC, and KYY had roles in the study design, data collection, data analysis, data interpretation, and writing of the manuscript. KKHC, CCYC, JOLT, RL, JC, KT, LLC, KW, JPC, ZWY, GL, HC and DYJ had roles in the experiments, data collection, data analysis, and/or data interpretation. All authors reviewed and approved the final version of the manuscript.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="par0100">JFWC has received travel grants from Pfizer Corporation Hong Kong and Astellas Pharma Hong Kong Corporation Limited, and was an invited speaker for Gilead Sciences Hong Kong Limited and Luminex Corporation. The other authors declared no conflict of interests. The funding sources had no role in study design, data collection, analysis or interpretation or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.</p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0005"><label>1</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>To</surname><given-names>K.K.</given-names></name><name><surname>Tse</surname><given-names>H.</given-names></name><name><surname>Jin</surname><given-names>D.Y.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Interspecies transmission and emergence of novel viruses: lessons from bats and birds</article-title><source>Trends Microbiol.</source><volume>21</volume><year>2013</year><fpage>544</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">23770275</pub-id></element-citation></ref><ref id="bib0010"><label>2</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>V.C.</given-names></name><name><surname>Lau</surname><given-names>S.K.</given-names></name><name><surname>Woo</surname><given-names>P.C.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection</article-title><source>Clin. Microbiol. Rev.</source><volume>20</volume><year>2007</year><fpage>660</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">17934078</pub-id></element-citation></ref><ref id="bib0015"><label>3</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Lau</surname><given-names>S.K.</given-names></name><name><surname>To</surname><given-names>K.K.</given-names></name><name><surname>Cheng</surname><given-names>V.C.</given-names></name><name><surname>Woo</surname><given-names>P.C.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease</article-title><source>Clin. Microbiol. Rev.</source><volume>28</volume><year>2015</year><fpage>465</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">25810418</pub-id></element-citation></ref><ref id="bib0020"><label>4</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Lu</surname><given-names>R.</given-names></name></person-group><article-title>A Novel Coronavirus from Patients with Pneumonia in China, 2019</article-title><source>N. Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">31978945</pub-id></element-citation></ref><ref id="bib0025"><label>5</label><element-citation publication-type="book" id="sbref0025"><person-group person-group-type="author"><name><surname>World Health Organization</surname></name></person-group><chapter-title>Coronavirus Disease 2019 (COVID-19) Situation Report &#x02013; 77</chapter-title><year>2020</year><ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200406-sitrep-77-covid-19.pdf?sfvrsn=21d1e632_2" id="intr0005">https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200406-sitrep-77-covid-19.pdf?sfvrsn=21d1e632_2</ext-link></element-citation></ref><ref id="bib0030"><label>6</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Kok</surname><given-names>K.H.</given-names></name><name><surname>To</surname><given-names>K.K.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Xing</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Yip</surname><given-names>C.C.</given-names></name><name><surname>Poon</surname><given-names>R.W.</given-names></name></person-group><article-title>A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>514</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">31986261</pub-id></element-citation></ref><ref id="bib0035"><label>7</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>D.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Qu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Jia</surname><given-names>R.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name></person-group><article-title>A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features</article-title><source>Clin. Infect. Dis.</source><year>2020</year><fpage>ciaa198</fpage><pub-id pub-id-type="doi">10.1093/cid/ciaa198</pub-id><comment>[Epub ahead of print]</comment><pub-id pub-id-type="pmid">32112072</pub-id></element-citation></ref><ref id="bib0040"><label>8</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name><surname>Verity</surname><given-names>R.</given-names></name><name><surname>Okell</surname><given-names>L.C.</given-names></name><name><surname>Dorigatti</surname><given-names>I.</given-names></name><name><surname>Winskill</surname><given-names>P.</given-names></name><name><surname>Whittaker</surname><given-names>C.</given-names></name><name><surname>Imai</surname><given-names>N.</given-names></name><name><surname>Cuomo-Dannenburg</surname><given-names>G.</given-names></name><name><surname>Thompson</surname><given-names>H.</given-names></name><name><surname>Walker</surname><given-names>P.G.T.</given-names></name><name><surname>Fu</surname><given-names>H.</given-names></name></person-group><article-title>Estimates of the severity of coronavirus disease 2019: a model-based analysis</article-title><source>Lancet Infect. Dis.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30243-7</pub-id><comment>pii: S1473-3099(20)30243-7. [Epub ahead of print]</comment></element-citation></ref><ref id="bib0045"><label>9</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W.J.</given-names></name><name><surname>Ni</surname><given-names>Z.Y.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>W.H.</given-names></name><name><surname>Ou</surname><given-names>C.Q.</given-names></name><name><surname>He</surname><given-names>J.X.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Shan</surname><given-names>H.</given-names></name><name><surname>Lei</surname><given-names>C.L.</given-names></name><name><surname>Hui</surname><given-names>D.S.C.</given-names></name></person-group><article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title><source>N. Engl. J. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="bib0050"><label>10</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Gu</surname><given-names>X.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="bib0055"><label>11</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Azhar</surname><given-names>E.I.</given-names></name><name><surname>Hui</surname><given-names>D.S.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Coronaviruses - drug discovery and therapeutic options</article-title><source>Nat. Rev. Drug Discov.</source><volume>15</volume><year>2016</year><fpage>327</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">26868298</pub-id></element-citation></ref><ref id="bib0060"><label>12</label><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Zhong</surname><given-names>W.</given-names></name><name><surname>Xiao</surname><given-names>G.</given-names></name></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title><source>Cell Res.</source><volume>30</volume><year>2020</year><fpage>269</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">32020029</pub-id></element-citation></ref><ref id="bib0065"><label>13</label><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name><surname>Gautret</surname><given-names>P.</given-names></name><name><surname>Lagier</surname><given-names>J.C.</given-names></name><name><surname>Parola</surname><given-names>P.</given-names></name><name><surname>Hoang</surname><given-names>V.T.</given-names></name><name><surname>Meddeb</surname><given-names>L.</given-names></name><name><surname>Mailhe</surname><given-names>M.</given-names></name><name><surname>Doudier</surname><given-names>B.</given-names></name><name><surname>Courjon</surname><given-names>J.</given-names></name><name><surname>Giordanengo</surname><given-names>V.</given-names></name><name><surname>Vieira</surname><given-names>V.E.</given-names></name></person-group><article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</article-title><source>Int. J. Antimicrob. Agents</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105949</pub-id><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="bib0070"><label>14</label><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M.</given-names></name><name><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name><surname>Schroeder</surname><given-names>S.</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N.</given-names></name><name><surname>Herrler</surname><given-names>T.</given-names></name><name><surname>Erichsen</surname><given-names>S.</given-names></name><name><surname>Schiergens</surname><given-names>T.S.</given-names></name><name><surname>Herrler</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>N.H.</given-names></name><name><surname>Nitsche</surname><given-names>A.</given-names></name></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><comment>pii: S0092-8674(20)30229-4. [Epub ahead of print]</comment></element-citation></ref><ref id="bib0075"><label>15</label><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name><surname>Caly</surname><given-names>L.</given-names></name><name><surname>Druce</surname><given-names>J.D.</given-names></name><name><surname>Catton</surname><given-names>M.G.</given-names></name><name><surname>Jans</surname><given-names>D.A.</given-names></name><name><surname>Wagstaff</surname><given-names>K.M.</given-names></name></person-group><article-title>The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 <italic>in vitro</italic></article-title><source>Antiviral Res.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104787</pub-id><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="bib0080"><label>16</label><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>X.</given-names></name><name><surname>Ye</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Cui</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Niu</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Dong</surname><given-names>E.</given-names></name><name><surname>Song</surname><given-names>C.</given-names></name></person-group><article-title>In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</article-title><source>Clin. Infect. Dis.</source><year>2020</year><fpage>ciaa237</fpage><pub-id pub-id-type="doi">10.1093/cid/ciaa237</pub-id><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="bib0085"><label>17</label><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Yuen</surname><given-names>T.T.</given-names></name><name><surname>Shuai</surname><given-names>H.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Yip</surname><given-names>C.C.</given-names></name><name><surname>Tsang</surname><given-names>J.O.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name></person-group><article-title>An observational study on the comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV: implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19</article-title><source>Lancet Microbe</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S2666-5247(20)30004-5</pub-id></element-citation></ref><ref id="bib0090"><label>18</label><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name><surname>Zaki</surname><given-names>A.M.</given-names></name><name><surname>van Boheemen</surname><given-names>S.</given-names></name><name><surname>Bestebroer</surname><given-names>T.M.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.</given-names></name></person-group><article-title>Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia</article-title><source>N. Engl. J. Med.</source><volume>367</volume><year>2013</year><fpage>1814</fpage><lpage>1820</lpage></element-citation></ref><ref id="bib0095"><label>19</label><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Chan</surname><given-names>K.H.</given-names></name><name><surname>Choi</surname><given-names>G.K.</given-names></name><name><surname>To</surname><given-names>K.K.</given-names></name><name><surname>Tse</surname><given-names>H.</given-names></name><name><surname>Cai</surname><given-names>J.P.</given-names></name><name><surname>Yeung</surname><given-names>M.L.</given-names></name><name><surname>Cheng</surname><given-names>V.C.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Che</surname><given-names>X.Y.</given-names></name></person-group><article-title>Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation</article-title><source>J. Infect. Dis.</source><volume>207</volume><year>2013</year><fpage>1743</fpage><lpage>1752</lpage><pub-id pub-id-type="pmid">23532101</pub-id></element-citation></ref><ref id="bib0100"><label>20</label><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Yuen</surname><given-names>T.T.</given-names></name><name><surname>Chai</surname><given-names>Y.</given-names></name><name><surname>Hou</surname><given-names>Y.</given-names></name><name><surname>Shuai</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name></person-group><article-title>Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19</article-title><source>Clin. Infect. Dis.</source><year>2020</year><comment>[accepted and in press]</comment></element-citation></ref><ref id="bib0105"><label>21</label><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Ye</surname><given-names>Z.W.</given-names></name><name><surname>Wen</surname><given-names>L.</given-names></name><name><surname>Yan</surname><given-names>B.</given-names></name><name><surname>Lai</surname><given-names>P.M.</given-names></name><name><surname>Tee</surname><given-names>K.M.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name></person-group><article-title>SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target</article-title><source>Nat. Commun.</source><volume>10</volume><year>2019</year><fpage>120</fpage><pub-id pub-id-type="pmid">30631056</pub-id></element-citation></ref><ref id="bib0110"><label>22</label><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name><surname>Che</surname><given-names>X.Y.</given-names></name><name><surname>Qiu</surname><given-names>L.W.</given-names></name><name><surname>Liao</surname><given-names>Z.Y.</given-names></name><name><surname>Wang</surname><given-names>Y.D.</given-names></name><name><surname>Wen</surname><given-names>K.</given-names></name><name><surname>Pan</surname><given-names>Y.X.</given-names></name><name><surname>Hao</surname><given-names>W.</given-names></name><name><surname>Mei</surname><given-names>Y.B.</given-names></name><name><surname>Cheng</surname><given-names>V.C.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43</article-title><source>J. Infect. Dis.</source><volume>191</volume><year>2005</year><fpage>2033</fpage><lpage>2037</lpage><pub-id pub-id-type="pmid">15897988</pub-id></element-citation></ref><ref id="bib0115"><label>23</label><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Zhang</surname><given-names>A.J.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Poon</surname><given-names>V.K.</given-names></name><name><surname>Chan</surname><given-names>C.C.</given-names></name><name><surname>Lee</surname><given-names>A.C.</given-names></name><name><surname>Chan</surname><given-names>W.M.</given-names></name><name><surname>Fan</surname><given-names>Z.</given-names></name><name><surname>Tsoi</surname><given-names>H.W.</given-names></name><name><surname>Wen</surname><given-names>L.</given-names></name></person-group><article-title>Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility</article-title><source>Clin. Infect. Dis.</source><year>2020</year><fpage>ciaa325</fpage><pub-id pub-id-type="doi">10.1093/cid/ciaa325</pub-id><comment>[Epub ahead of print]</comment><pub-id pub-id-type="pmid">32215622</pub-id></element-citation></ref><ref id="bib0120"><label>24</label><element-citation publication-type="journal" id="sbref0120"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Chan</surname><given-names>K.H.</given-names></name><name><surname>Kao</surname><given-names>R.Y.</given-names></name><name><surname>To</surname><given-names>K.K.</given-names></name><name><surname>Zheng</surname><given-names>B.J.</given-names></name><name><surname>Li</surname><given-names>C.P.</given-names></name><name><surname>Li</surname><given-names>C.P.T.</given-names></name><name><surname>Dai</surname><given-names>J.</given-names></name><name><surname>Mok</surname><given-names>F.K.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name></person-group><article-title>Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus</article-title><source>J. Infect.</source><volume>67</volume><year>2013</year><fpage>606</fpage><lpage>616</lpage><pub-id pub-id-type="pmid">24096239</pub-id></element-citation></ref><ref id="bib0125"><label>25</label><element-citation publication-type="journal" id="sbref0125"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Singh</surname><given-names>K.</given-names></name><name><surname>Chow</surname><given-names>B.K.</given-names></name><name><surname>Kao</surname><given-names>R.Y.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>B.J.</given-names></name></person-group><article-title>Identification of a small-molecule inhibitor of influenza virus via disrupting the subunits interaction of the viral polymerase</article-title><source>Antiviral Res.</source><volume>125</volume><year>2016</year><fpage>34</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">26593979</pub-id></element-citation></ref><ref id="bib0130"><label>26</label><element-citation publication-type="journal" id="sbref0130"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Yip</surname><given-names>C.C.</given-names></name><name><surname>To</surname><given-names>K.K.</given-names></name><name><surname>Tang</surname><given-names>T.H.</given-names></name><name><surname>Wong</surname><given-names>S.C.</given-names></name><name><surname>Leung</surname><given-names>K.H.</given-names></name><name><surname>Fung</surname><given-names>A.Y.</given-names></name><name><surname>Ng</surname><given-names>A.C.</given-names></name><name><surname>Zou</surname><given-names>Z.</given-names></name><name><surname>Tsoi</surname><given-names>H.W.</given-names></name></person-group><article-title>Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens</article-title><source>J. Clin. Microbiol.</source><year>2020</year><pub-id pub-id-type="doi">10.1128/JCM.00310-20</pub-id><comment>pii: JCM.00310-20. [Epub ahead of print]</comment></element-citation></ref><ref id="bib0135"><label>27</label><element-citation publication-type="journal" id="sbref0135"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Ye</surname><given-names>J.</given-names></name><name><surname>Singh</surname><given-names>K.</given-names></name><name><surname>Kao</surname><given-names>R.Y.</given-names></name><name><surname>Chow</surname><given-names>B.K.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>B.J.</given-names></name></person-group><article-title>A novel small-molecule compound disrupts influenza A virus PB2 cap-binding and inhibits viral replication</article-title><source>J. Antimicrob. Chemother.</source><volume>71</volume><year>2016</year><fpage>2489</fpage><lpage>2497</lpage><pub-id pub-id-type="pmid">27272726</pub-id></element-citation></ref><ref id="bib0140"><label>28</label><element-citation publication-type="journal" id="sbref0140"><person-group person-group-type="author"><name><surname>Bryson</surname><given-names>A.</given-names></name><name><surname>de la Motte</surname><given-names>S.</given-names></name><name><surname>Dunk</surname><given-names>C.</given-names></name></person-group><article-title>Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers</article-title><source>Br. J. Clin. Pharmacol.</source><volume>67</volume><year>2009</year><fpage>309</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">19220279</pub-id></element-citation></ref><ref id="bib0145"><label>29</label><element-citation publication-type="journal" id="sbref0145"><person-group person-group-type="author"><name><surname>Rickards</surname><given-names>A.G.</given-names></name></person-group><article-title>The treatment of amoebiasis with diodoquin</article-title><source>J. Trop. Med. Hyg.</source><volume>52</volume><year>1949</year><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">18111812</pub-id></element-citation></ref><ref id="bib0150"><label>30</label><element-citation publication-type="journal" id="sbref0150"><person-group person-group-type="author"><name><surname>Padwal</surname><given-names>R.</given-names></name></person-group><article-title>Cetilistat, a new lipase inhibitor for the treatment of obesity</article-title><source>Curr. Opin. Investig. Drugs</source><volume>9</volume><year>2008</year><fpage>414</fpage><lpage>421</lpage></element-citation></ref><ref id="bib0155"><label>31</label><element-citation publication-type="journal" id="sbref0155"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>K.S.</given-names></name><name><surname>Hung</surname><given-names>I.F.</given-names></name><name><surname>Chan</surname><given-names>P.P.</given-names></name><name><surname>Lung</surname><given-names>K.C.</given-names></name><name><surname>Tso</surname><given-names>E.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Ng</surname><given-names>Y.Y.</given-names></name><name><surname>Chu</surname><given-names>M.Y.</given-names></name><name><surname>Chung</surname><given-names>T.W.</given-names></name><name><surname>Tam</surname><given-names>A.R.</given-names></name></person-group><article-title>Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and meta-analysis</article-title><source>Gastroenterology</source><year>2020</year><pub-id pub-id-type="doi">10.1053/j.gastro.2020.03.065</pub-id><comment>pii: S0016-5085(20)30448-0. [Epub ahead of print]</comment></element-citation></ref><ref id="bib0160"><label>32</label><element-citation publication-type="journal" id="sbref0160"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>I.F.</given-names></name><name><surname>Cheng</surname><given-names>V.C.</given-names></name><name><surname>Wu</surname><given-names>A.K.</given-names></name><name><surname>Tang</surname><given-names>B.S.</given-names></name><name><surname>Chan</surname><given-names>K.H.</given-names></name><name><surname>Chu</surname><given-names>C.M.</given-names></name><name><surname>Wong</surname><given-names>M.M.</given-names></name><name><surname>Hui</surname><given-names>W.T.</given-names></name><name><surname>Poon</surname><given-names>L.L.</given-names></name><name><surname>Tse</surname><given-names>D.M.</given-names></name></person-group><article-title>Viral loads in clinical specimens and SARS manifestations</article-title><source>Emerg Infect Dis.</source><volume>10</volume><year>2004</year><fpage>1550</fpage><lpage>1557</lpage><pub-id pub-id-type="pmid">15498155</pub-id></element-citation></ref><ref id="bib0165"><label>33</label><element-citation publication-type="journal" id="sbref0165"><person-group person-group-type="author"><name><surname>Duc</surname><given-names>I.</given-names></name><name><surname>Bonnet</surname><given-names>P.</given-names></name><name><surname>Duranti</surname><given-names>V.</given-names></name><name><surname>Cardinali</surname><given-names>S.</given-names></name><name><surname>Riviere</surname><given-names>A.</given-names></name><name><surname>De Giovanni</surname><given-names>A.</given-names></name><name><surname>Shields-Botella</surname><given-names>J.</given-names></name><name><surname>Barcelo</surname><given-names>G.</given-names></name><name><surname>Adje</surname><given-names>N.</given-names></name><name><surname>Carniato</surname><given-names>D.</given-names></name></person-group><article-title>) In vitro and in vivo models for the evaluation of potent inhibitors of male rat 17alpha-hydroxylase/C17,20-lyase</article-title><source>J. Steroid Biochem. Mol. Biol.</source><volume>84</volume><year>2003</year><fpage>537</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">12767278</pub-id></element-citation></ref><ref id="bib0170"><label>34</label><element-citation publication-type="journal" id="sbref0170"><person-group person-group-type="author"><name><surname>Arasaratnam</surname><given-names>M.</given-names></name><name><surname>Crumbaker</surname><given-names>M.</given-names></name><name><surname>Bhatnagar</surname><given-names>A.</given-names></name><name><surname>McKay</surname><given-names>Mj</given-names></name><name><surname>Molloy</surname><given-names>Mp</given-names></name><name><surname>Gurney</surname><given-names>H.</given-names></name></person-group><article-title>Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer</article-title><source>Cancer Chemother. Pharmacol.</source><volume>84</volume><year>2019</year><fpage>139</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">31081533</pub-id></element-citation></ref><ref id="bib0175"><label>35</label><element-citation publication-type="journal" id="sbref0175"><person-group person-group-type="author"><name><surname>Boehm</surname><given-names>M.F.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhi</surname><given-names>L.</given-names></name><name><surname>McClurg</surname><given-names>M.R.</given-names></name><name><surname>Berger</surname><given-names>E.</given-names></name><name><surname>Wagoner</surname><given-names>M.</given-names></name><name><surname>Mais</surname><given-names>D.E.</given-names></name><name><surname>Suto</surname><given-names>C.M.</given-names></name></person-group><article-title>Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells</article-title><source>J. Med. Chem.</source><volume>38</volume><year>1995</year><fpage>3146</fpage><lpage>3155</lpage><pub-id pub-id-type="pmid">7636877</pub-id></element-citation></ref><ref id="bib0180"><label>36</label><element-citation publication-type="journal" id="sbref0180"><person-group person-group-type="author"><name><surname>Gniadecki</surname><given-names>R.</given-names></name><name><surname>Assaf</surname><given-names>C.</given-names></name><name><surname>Bagot</surname><given-names>M.</given-names></name><name><surname>Dummer</surname><given-names>R.</given-names></name><name><surname>Duvic</surname><given-names>M.</given-names></name><name><surname>Knobler</surname><given-names>R.</given-names></name><name><surname>Ranki</surname><given-names>A.</given-names></name><name><surname>Schwandt</surname><given-names>P.</given-names></name><name><surname>Whittaker</surname><given-names>S.</given-names></name></person-group><article-title>The optimal use of bexarotene in cutaneous T-cell lymphoma</article-title><source>Br. J. Dermatol.</source><volume>157</volume><year>2007</year><fpage>433</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">17553039</pub-id></element-citation></ref><ref id="bib0185"><label>37</label><element-citation publication-type="journal" id="sbref0185"><person-group person-group-type="author"><name><surname>Dragnev</surname><given-names>K.H.</given-names></name><name><surname>Petty</surname><given-names>W.J.</given-names></name><name><surname>Shah</surname><given-names>S.J.</given-names></name><name><surname>Lewis</surname><given-names>L.D.</given-names></name><name><surname>Black</surname><given-names>C.C.</given-names></name><name><surname>Memoli</surname><given-names>V.</given-names></name><name><surname>Nugent</surname><given-names>W.C.</given-names></name><name><surname>Hermann</surname><given-names>T.</given-names></name><name><surname>Negro-Vilar</surname><given-names>A.</given-names></name><name><surname>Rigas</surname><given-names>J.R.</given-names></name></person-group><article-title>A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer</article-title><source>Clin. Cancer Res.</source><volume>13</volume><year>2007</year><fpage>1794</fpage><lpage>1800</lpage><pub-id pub-id-type="pmid">17363535</pub-id></element-citation></ref><ref id="bib0190"><label>38</label><element-citation publication-type="journal" id="sbref0190"><person-group person-group-type="author"><name><surname>Esteva</surname><given-names>F.J.</given-names></name><name><surname>Glaspy</surname><given-names>J.</given-names></name><name><surname>Baidas</surname><given-names>S.</given-names></name><name><surname>Laufman</surname><given-names>L.</given-names></name><name><surname>Hutchins</surname><given-names>L.</given-names></name><name><surname>Dickler</surname><given-names>M.</given-names></name><name><surname>Tripathy</surname><given-names>D.</given-names></name><name><surname>Cohen</surname><given-names>R.</given-names></name></person-group><article-title>Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer</article-title><source>J. Clin. Oncol.</source><volume>21</volume><year>2003</year><fpage>999</fpage><lpage>1006</lpage><pub-id pub-id-type="pmid">12637463</pub-id></element-citation></ref><ref id="bib0195"><label>39</label><element-citation publication-type="journal" id="sbref0195"><person-group person-group-type="author"><name><surname>Liston</surname><given-names>D.R.</given-names></name><name><surname>Davis</surname><given-names>M.</given-names></name></person-group><article-title>Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies</article-title><source>Clin. Cancer Res.</source><volume>23</volume><year>2017</year><fpage>3489</fpage><lpage>3498</lpage><pub-id pub-id-type="pmid">28364015</pub-id></element-citation></ref></ref-list><ack id="ack0005"><title>Acknowledgements</title><p>This study was partly supported by funding from <funding-source id="gs0005">Health@InnoHK (Centre for Virology, Vaccinology and Therapeutics)</funding-source>, <funding-source id="gs0010"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100003452</institution-id><institution>Innovation and Technology Commission</institution></institution-wrap></funding-source>, <funding-source id="gs0015">The Government of the Hong Kong Special Administrative Region of the People&#x02019;s Republic of China</funding-source>; the <funding-source id="gs0020">National Program on Key Research Project of China</funding-source> (grant no. 2020YFA0707500 and 2020YFA0707504); the <funding-source id="gs0025">Theme-Based Research Scheme</funding-source> (T11/707/15) of the <funding-source id="gs0030">Research Grants Council, Hong Kong Special Administrative Region; and the High Level-Hospital Program</funding-source>, <funding-source id="gs0035">Health Commission of Guangdong Province, China</funding-source>; and donations of Richard Yu and Carol Yu, the Shaw Foundation of Hong Kong, Michael Seak-Kan Tong, May Tam Mak Mei Yin, Respiratory Viral Research Foundation Limited, Hui Ming, Hui Hoy and Chow Sin Lan Charity Fund Limited, Chan Yin Chuen Memorial Charitable Foundation, Marina Man-Wai Lee, the Hong Kong Hainan Commercial Association South China Microbiology Research Fund, the Jessie &#x00026; George Ho Charitable Foundation, Perfect Shape Medical Limited, and Kai Chong Tong. The funding sources had no role in the study design, data collection, analysis, interpretation, or writing of the report.</p></ack></back></article>